JP2015513544A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015513544A5 JP2015513544A5 JP2014559183A JP2014559183A JP2015513544A5 JP 2015513544 A5 JP2015513544 A5 JP 2015513544A5 JP 2014559183 A JP2014559183 A JP 2014559183A JP 2014559183 A JP2014559183 A JP 2014559183A JP 2015513544 A5 JP2015513544 A5 JP 2015513544A5
- Authority
- JP
- Japan
- Prior art keywords
- chem
- glp
- compound according
- peptide
- amide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 12
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 10
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 150000001408 amides Chemical class 0.000 claims 5
- 150000002148 esters Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 102000009027 Albumins Human genes 0.000 claims 3
- 108010088751 Albumins Proteins 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000002249 Diabetes Complications Diseases 0.000 claims 2
- 206010012655 Diabetic complications Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- -1 GLP-1 compound Chemical class 0.000 claims 1
- ACZFBYCNAVEFLC-UHFFFAOYSA-N Imidazole lactic acid Natural products OC(=O)C(O)CC1=CN=CN1 ACZFBYCNAVEFLC-UHFFFAOYSA-N 0.000 claims 1
- 206010036049 Polycystic ovaries Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 0 CC[C@](C)[C@@](C(N[C@@](C(C)C)C(O[C@@](Cc1c[n]cn1)C(NC(C)(C)C(*)=O)=O)=O)=O)NC Chemical compound CC[C@](C)[C@@](C(N[C@@](C(C)C)C(O[C@@](Cc1c[n]cn1)C(NC(C)(C)C(*)=O)=O)=O)=O)NC 0.000 description 4
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12157638 | 2012-03-01 | ||
| EP12157638.3 | 2012-03-01 | ||
| PCT/EP2013/053796 WO2013127779A1 (en) | 2012-03-01 | 2013-02-26 | Glp-1 prodrugs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015513544A JP2015513544A (ja) | 2015-05-14 |
| JP2015513544A5 true JP2015513544A5 (enExample) | 2016-03-03 |
| JP6300735B2 JP6300735B2 (ja) | 2018-03-28 |
Family
ID=47748659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014559183A Active JP6300735B2 (ja) | 2012-03-01 | 2013-02-26 | Glp−1プロドラッグ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9452225B2 (enExample) |
| EP (1) | EP2820038B1 (enExample) |
| JP (1) | JP6300735B2 (enExample) |
| CN (1) | CN104185639B (enExample) |
| ES (1) | ES2810153T3 (enExample) |
| WO (1) | WO2013127779A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4442314A2 (en) | 2015-10-28 | 2024-10-09 | Tufts University | Novel polypeptides with improved proteolytic stability, and methods of preparing and using same |
| CN118903386A (zh) | 2017-08-24 | 2024-11-08 | 诺和诺德股份有限公司 | Glp-1组合物及其用途 |
| CN109942696A (zh) * | 2017-12-21 | 2019-06-28 | 中国药科大学 | 长效化胰高血糖素样肽-1(glp-1)类似物及其应用 |
| JP7422754B2 (ja) | 2018-10-26 | 2024-01-26 | ノヴォ ノルディスク アー/エス | 安定性セマグルチド組成物およびその使用 |
| KR20220143036A (ko) | 2020-02-18 | 2022-10-24 | 노보 노르디스크 에이/에스 | 약학적 제형 |
| CN113336840B (zh) * | 2020-03-02 | 2022-09-23 | 武汉帕肽生物医药有限责任公司 | 订书肽、其制备方法和用途 |
| US20210318292A1 (en) * | 2020-04-13 | 2021-10-14 | Sensorium Bio, Inc. | System and Method to Detect Small Molecules |
| US20250268986A1 (en) | 2020-11-06 | 2025-08-28 | Novo Nordisk A/S | Glp-1 prodrugs and uses thereof |
| AR129270A1 (es) | 2022-05-10 | 2024-08-07 | Novo Nordisk As | Profármacos y usos de los mismos |
| CN120659805A (zh) * | 2023-10-31 | 2025-09-16 | 深圳信立泰药业股份有限公司 | Glp-1化合物及其制备方法与应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61143400A (ja) * | 1984-12-17 | 1986-07-01 | Kenji Okawa | アクチノマイシンd様ペプチド |
| US4966848A (en) * | 1988-02-08 | 1990-10-30 | The General Hospital Corporation | Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase |
| US5223421A (en) * | 1989-10-25 | 1993-06-29 | The General Hospital Corporation | Identification of methionine Nα-acetyltransferase |
| US5688489A (en) * | 1995-09-15 | 1997-11-18 | Resolution Pharmaceuticals, Inc. | Non-receptor mediated imaging agents |
| FR2777283B1 (fr) * | 1998-04-10 | 2000-11-24 | Adir | Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US20040235726A1 (en) * | 2001-10-01 | 2004-11-25 | Jakubowski Joseph Anthony | Glucagon-like peptides (glp-1) and treatment of respiratory distress |
| ES2438145T3 (es) | 2005-02-02 | 2014-01-16 | Novo Nordisk A/S | Nuevos derivados de insulina |
| EP2514406A1 (en) | 2007-06-01 | 2012-10-24 | Novo Nordisk A/S | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier |
| US8895694B2 (en) | 2007-09-05 | 2014-11-25 | Novo Nordisk A/S | Glucagon-Like Peptide-1 derivatives and their pharmaceutical use |
| CN101220088B (zh) * | 2007-09-24 | 2012-01-25 | 中国人民解放军第四军医大学 | 人胰高血糖素样肽-1类似物的融合蛋白及其应用 |
| EP2214691B1 (en) | 2007-10-30 | 2015-09-30 | Indiana University Research and Technology Corporation | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
| AU2008318986B2 (en) | 2007-10-30 | 2014-12-04 | Indiana University Research And Technology Corporation | Glucagon antagonists |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| WO2009099763A1 (en) | 2008-01-30 | 2009-08-13 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
| CN102300580A (zh) | 2008-12-19 | 2011-12-28 | 印第安纳大学研究及科技有限公司 | 二肽连接的药剂 |
| WO2010071807A1 (en) | 2008-12-19 | 2010-06-24 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
| WO2011080102A2 (en) | 2009-12-16 | 2011-07-07 | Novo Nordisk A/S | Glp-1 analogues and derivatives |
| US8778872B2 (en) * | 2010-06-24 | 2014-07-15 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
-
2013
- 2013-02-26 WO PCT/EP2013/053796 patent/WO2013127779A1/en not_active Ceased
- 2013-02-26 US US14/379,445 patent/US9452225B2/en active Active
- 2013-02-26 ES ES13705822T patent/ES2810153T3/es active Active
- 2013-02-26 CN CN201380011989.XA patent/CN104185639B/zh active Active
- 2013-02-26 JP JP2014559183A patent/JP6300735B2/ja active Active
- 2013-02-26 EP EP13705822.8A patent/EP2820038B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015513544A5 (enExample) | ||
| RU2012128547A (ru) | Дважды ацилированные производные glp-1 | |
| JP2013530974A5 (enExample) | ||
| JP2011526886A5 (enExample) | ||
| JP2017500289A5 (enExample) | ||
| WO2013002580A3 (ko) | 폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물 | |
| JP2018506507A5 (enExample) | ||
| JP2013533227A5 (enExample) | ||
| RU2015147876A (ru) | Пероральная дозированная форма соединений глюкагоноподобного пептида-1 | |
| JP2014503526A5 (enExample) | ||
| TN2012000215A1 (en) | Pharmaceutical compositions comprising a g l p -1 agonist and methionine | |
| WO2009011544A3 (en) | Insulinotropic peptide derivative wherein its n-terminal amino acid is modified | |
| JP2013542247A5 (enExample) | ||
| JP2018522843A5 (enExample) | ||
| MX355361B (es) | Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados. | |
| RU2016135543A (ru) | Новые производные инсулина и их применение в медицине | |
| EP2581376A4 (en) | MATRINIC ACID / MATRINE DERIVATIVES AND METHODS OF PREPARATION AND USES THEREOF | |
| WO2009076173A3 (en) | Fluorinated tripeptide hcv serine protease inhibitors | |
| ME02666B (me) | Cefalosporin sa kateholskom grupom | |
| WO2008021871A3 (en) | Triazolyl acyclic hepatitis c serine protease inhibitors | |
| JP2018505146A5 (enExample) | ||
| JP2013520405A5 (enExample) | ||
| JP2016519106A5 (enExample) | ||
| JP2016532716A5 (enExample) | ||
| JP2010523476A5 (enExample) |